De novo exon 18 G724S point mutation may be sensitive to Gefitinib

Kaohsiung J Med Sci. 2021 Oct;37(10):918-919. doi: 10.1002/kjm2.12412. Epub 2021 Jun 29.

Authors

Tai-Huang Lee¹, Chih-Jen Yang^{1

2

3}

Affiliations

¹ Department of Internal Medicine, Kaohsiung Municipal University Hospital, Kaohsiung, Taiwan.
² School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
³ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan.

PMID: 34184414
DOI: 10.1002/kjm2.12412

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Exons*
Female
Gefitinib / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Male
Middle Aged
Point Mutation*

Substances

Antineoplastic Agents
Gefitinib